乌司奴单抗再诱导和/或剂量递增治疗克罗恩病的有效性:系统综述与荟萃分析
该系统综述与荟萃分析纳入15项队列研究、925例对标准剂量乌司奴单抗应答不足或失应答的成人克罗恩病患者,评估再诱导和/或缩短给药间隔的有效性。汇总分析显示55%患者获得临床应答,61%获得内镜应答(其中29%内镜缓解),仅缩短给药间隔即可使57%患者重获应答。
要点
- 对标准剂量乌司奴单抗应答不足或失应答的克罗恩病患者,剂量递增后55%获得临床应答。
- 剂量递增后约61%患者获得内镜应答,29%达到内镜缓解。
- 仅缩短给药间隔至<8周即可使57%患者重获应答。
核心结论
- 真实世界背景下,对标准剂量诱导和/或维持治疗应答不足或失应答的克罗恩病患者,乌司奴单抗剂量递增(再诱导和/或缩短给药间隔)仍能有效获得应答。
研究设计与样本
- 系统综述与荟萃分析,检索截至2021年3月31日的文献,纳入15项队列研究、925例对标准剂量乌司奴单抗应答不足或失应答并接受剂量递增(再诱导和/或给药间隔缩短至<8周)的成人克罗恩病患者。
主要发现
- 荟萃分析显示,接受乌司奴单抗剂量递增的患者中55%(95%CI 52%-58%)获得临床应答,异质性中等(I2=57%)。
- 约61%患者获得内镜应答,其中29%达到内镜缓解。
- 仅缩短给药间隔即可使57%患者重获应答。
- 定性汇总未识别出一致的与剂量递增应答相关的因素。
关键数值与推荐
- 临床应答率55%(95%CI 52%-58%),异质性I2=57%。
- 内镜应答率约61%,内镜缓解率29%。
- 仅缩短给药间隔的应答重获率57%。
临床怎么用
- 对标准剂量乌司奴单抗应答不足或失应答的克罗恩病患者,可考虑再诱导和/或缩短给药间隔以重获临床及内镜应答。
局限性
- 纳入研究均为队列研究,存在观察性设计固有偏倚。
- 临床应答汇总存在中等异质性(I2=57%)。
- 定性汇总未识别出一致的与剂量递增应答相关的因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Patients with Crohn's disease (CD) treated with ustekinumab who experience inadequate response, or loss of response after standard induction and/or maintenance dosing may benefit from dose escalation. We conducted a systematic review and meta-analysis examining the effectiveness of reinduction and/or dose interval shortening of ustekinumab in patients with active CD despite standard induction and maintenance. METHODS: Through a systematic literature search through March 31, 2021, we identified 15 cohort studies in 925 adults with CD with inadequate response or loss of response to standard dose ustekinumab, underwent dose escalation (reinduction and/or dose interval shortening to <8 weeks), and reported rates of achieving clinical response, corticosteroid-free clinical remission, endoscopic response, and/or remission. We calculated pooled rates (with 95% confidence intervals) using random effects meta-analysis and examined factors associated with response to dose escalation through qualitative synthesis of individual studies. RESULTS: On meta-analysis, 55% of patients (95% confidence interval, 52%-58%) with inadequate response or loss of response who underwent ustekinumab dose escalation achieved clinical response, with moderate heterogeneity (I2 = 57%). Approximately 61% of patients were able to achieve endoscopic response, including 29% who achieved endoscopic remission. Dose interval shortening alone recaptured response in 57% patients. No consistent factors associated with response to dose escalation were identified on qualitative synthesis. CONCLUSION: In real word settings, ustekinumab dose escalation was effective in achieving response in patients with CD with inadequate response, or loss of response to standard dose induction and/or maintenance therapy.
引用
- Meserve J, Ma C, Dulai PS, et al. Effectiveness of Reinduction and/or Dose Escalation of Ustekinumab in Crohn's Disease: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2021. PMID: 34628078. doi:10.1016/j.cgh.2021.10.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。